Aravind Eye Care System
13
2
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
38%
5 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Parasitic Ulcer Treatment Trial
Role: collaborator
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Role: collaborator
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II
Role: collaborator
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
Role: collaborator
Steroids and Cross-linking for Ulcer Treatment
Role: collaborator
Perfecting Refraction in India With Superior Service Models
Role: collaborator
Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients
Role: collaborator
Investigation of the Accuracy of a Low-cost, Portable, Autorefractor to Provide Well-tolerated Eyeglass Prescriptions
Role: collaborator
PROductivity Study of Presbyopia Elimination in Rural-dwellers (PROSPER)
Role: collaborator
Study of Effectiveness of Telemedicine in Identifying Diabetic Retinopathy Cases
Role: lead
Clinical & Visual Outcomes of Collagen Cross Linking for Fungal Keratitis
Role: lead
Corneal Ulcer Prevention Through Health Education
Role: lead
Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection
Role: lead
All 13 trials loaded